Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL) today. The company’s shares opened today at $24.33, close to its 52-week high of $25.31.
Tuerkcan has an average return of 7.5% when recommending Exelixis.
According to TipRanks.com, Tuerkcan is ranked #1963 out of 5262 analysts.
Currently, the analyst consensus on Exelixis is a Strong Buy with an average price target of $32.38.
See today’s analyst top recommended stocks >>
Exelixis’ market cap is currently $7.22B and has a P/E ratio of 10.95. The company has a Price to Book ratio of 7.88.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. Last month, Stelios Papadopoulos, a Director at EXEL sold 26,250 shares for a total of $557,813.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.
